| scholarly article | Q13442814 |
| P356 | DOI | 10.3892/OL.2017.6409 |
| P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530221 |
| P932 | PMC publication ID | 5530221 |
| P698 | PubMed publication ID | 28781693 |
| P50 | author | Yasushi Yatabe | Q56697495 |
| Daisuke Takahari | Q87662858 | ||
| Masashi Ando | Q90096247 | ||
| P2093 | author name string | Masako Asayama | |
| Tetsuya Eto | |||
| Takashi Ura | |||
| Kei Muro | |||
| Hiroya Taniguchi | |||
| Masahiro Tajika | |||
| Yasumasa Niwa | |||
| Kensei Yamaguchi | |||
| Hiroki Hara | |||
| Shigenori Kadowaki | |||
| Yukiya Narita | |||
| Toshiki Masuishi | |||
| P2860 | cites work | Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. | Q27851468 |
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 | ||
| Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 | ||
| Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression | Q33400932 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer | Q34366342 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis | Q34655369 | ||
| Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients | Q37135262 | ||
| Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know | Q37774807 | ||
| Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population | Q38083585 | ||
| Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 | ||
| Clinical significance of intratumoral HER2 heterogeneity in gastric cancer | Q45406819 | ||
| Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 | ||
| Impact of trastuzumab treatment beyond disease progression for advanced/metastatic breast cancer on survival - results from a prospective, observational study in Germany. | Q52875534 | ||
| Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 | ||
| Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 | ||
| Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. | Q53645618 | ||
| Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. | Q54591190 | ||
| Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay | Q77925384 | ||
| Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group | Q80704657 | ||
| P433 | issue | 2 | |
| P921 | main subject | trastuzumab | Q412616 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| P304 | page(s) | 2545-2551 | |
| P577 | publication date | 2017-06-19 | |
| P1433 | published in | Oncology Letters | Q20640514 |
| P1476 | title | Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer | |
| P478 | volume | 14 |
| Q89795555 | Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives | cites work | P2860 |
Search more.